Harmony Biosciences Holdings Inc (HRMY)
28.81
-0.58
(-1.97%)
USD |
NASDAQ |
Apr 23, 16:00
28.81
0.00 (0.00%)
After-Hours: 18:11
Harmony Biosciences Holdings Total Liabilities (Quarterly): 344.46M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 344.46M |
| September 30, 2023 | 296.43M |
| June 30, 2023 | 275.01M |
| March 31, 2023 | 272.05M |
| December 31, 2022 | 271.03M |
| September 30, 2022 | 299.58M |
| June 30, 2022 | 258.50M |
| March 31, 2022 | 249.50M |
| December 31, 2021 | 246.94M |
| Date | Value |
|---|---|
| September 30, 2021 | 239.07M |
| June 30, 2021 | 233.14M |
| March 31, 2021 | 229.37M |
| December 31, 2020 | 329.89M |
| September 30, 2020 | 225.52M |
| June 30, 2020 | 218.17M |
| March 31, 2020 | 212.78M |
| December 31, 2019 | 118.29M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
118.29M
Minimum
Dec 2019
344.46M
Maximum
Dec 2023
254.10M
Average
249.50M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Amylyx Pharmaceuticals Inc | 84.02M |
| Exelixis Inc | 678.44M |
| Insmed Inc | 1.662B |
| Arcturus Therapeutics Holdings Inc | 150.89M |
| Ultragenyx Pharmaceutical Inc | 1.216B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 811.45M |
| Shareholders Equity (Quarterly) | 466.99M |
| Debt to Equity Ratio | 0.4145 |
| Current Ratio | 2.754 |
| Net Debt Paydown Yield | -0.02% |